298 related articles for article (PubMed ID: 26179177)
1. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.
Helseth R; Carlsen SM; Bollerslev J; Svartberg J; Øksnes M; Skeie S; Fougner SL
Endocrine; 2016 Feb; 51(2):298-307. PubMed ID: 26179177
[TBL] [Abstract][Full Text] [Related]
2. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
3. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
[TBL] [Abstract][Full Text] [Related]
4. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
[TBL] [Abstract][Full Text] [Related]
5. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
[TBL] [Abstract][Full Text] [Related]
6. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study.
Colao A; Auriemma RS; Galdiero M; Cappabianca P; Cavallo LM; Esposito F; Grasso LF; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Feb; 94(2):528-37. PubMed ID: 19001517
[TBL] [Abstract][Full Text] [Related]
7. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
[TBL] [Abstract][Full Text] [Related]
8. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
9. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.
Barkan AL; Burman P; Clemmons DR; Drake WM; Gagel RF; Harris PE; Trainer PJ; van der Lely AJ; Vance ML
J Clin Endocrinol Metab; 2005 Oct; 90(10):5684-91. PubMed ID: 16076947
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery.
Chen HS; Wu TE; Jap TS; Hsiao LC; Lin HD; Lee SH; Lin SH
Horm Metab Res; 2011 Jun; 43(6):433-9. PubMed ID: 21538290
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
12. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
Valea A; Carsote M; Ghervan C; Georgescu C
J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
14. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
15. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
[TBL] [Abstract][Full Text] [Related]
16. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
17. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
19. Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly.
Fahlbusch R; Kleinberg D; Biller B; Bonert V; Buchfelder M; Cappabianca P; Carmichael J; Chandler W; Colao A; George A; Klibanski A; Knopp E; Kreutzer J; Kundurti N; Lesser M; Mamelak A; Pivonello R; Post K; Swearingen B; Vance ML; Barkan A
Pituitary; 2017 Dec; 20(6):668-675. PubMed ID: 28825168
[TBL] [Abstract][Full Text] [Related]
20. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
